Valuation: China Shineway Pharmaceutical Group Limited

Market Cap 4.72B 5.53B 705M 627M 585M 533M 1.01B 67.87B 1.01B 7.09B 2.75B 34.67B 2.65B 2.59B 111B P/E 2026 *
6.25x
P/E 2027 * 5.82x
Enterprise Value 4.72B 5.53B 705M 627M 585M 533M 1.01B 67.87B 1.01B 7.09B 2.75B 34.67B 2.65B 2.59B 111B EV / Sales 2026 *
2.01x
EV / Sales 2027 * 2.01x
Free-Float
33.69%
Yield 2026 *
-
Yield 2027 * -
1 day-0.41%
1 week-12.71%
Current month-12.29%
1 month-10.25%
3 months-0.88%
6 months-25.05%
Current year-14.94%
1 week 7.12
Extreme 7.12
8.56
1 month 7.12
Extreme 7.12
8.56
Current year 7.12
Extreme 7.12
10.47
1 year 7.12
Extreme 7.12
10.47
3 years 6.55
Extreme 6.55
10.76
5 years 4.63
Extreme 4.63
10.76
10 years 4.6
Extreme 4.6
18.54
Manager TitleAgeSince
Investor Relations Contact 60 -
Sales & Marketing 46 30/11/2019
Comptroller/Controller/Auditor 53 31/01/2011
Director TitleAgeSince
Chairman 70 13/08/2002
Director/Board Member 58 -
Director/Board Member 50 30/09/2020
Date Insider Type Main position Quantity % Market Cap. Importance
31/10/22 Other

Director

280,000 0.0339%
Change 5-day change 1-year change 3-year change Capi.($)
-0.41%-12.71%-13.02%-6.58% 704M
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.73%-4.32%+23.15%+50.78% 369.79B
Weighted average by Cap. -0.60%-3.33%+30.51%+68.94%

Financials

2026 *2027 *
Net sales 2.34B 2.75B 350M 311M 290M 265M 500M 33.7B 503M 3.52B 1.36B 17.21B 1.31B 1.29B 55.23B 2.35B 2.75B 350M 312M 291M 265M 500M 33.74B 504M 3.52B 1.37B 17.24B 1.32B 1.29B 55.3B
Net income 755M 884M 113M 100M 93.52M 85.25M 161M 10.85B 162M 1.13B 440M 5.54B 423M 414M 17.79B 811M 950M 121M 108M 100M 91.58M 173M 11.66B 174M 1.22B 472M 5.96B 455M 445M 19.11B
Net Debt - -
Logo China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Employees
2,656
Date Price Change Volume
02/10/26 HK$7.315 -12.29% 2,431,190
30/09/26 HK$8.340 -0.42% 3,937,453
29/09/26 HK$8.375 -1.24% 2,284,000
28/09/26 HK$8.480 +1.19% 2,561,000
25/09/26 HK$8.380 +0.30% 487,000
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
6.250CNY
Average target price
7.294CNY
Spread / Average Target
+16.70%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2877 Stock